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Background: Continuous long-term treatment is recommended to reduce the hepatitis B virus (HBV) viral load.
However, as a consequence, resistance mutations can emerge and be transmitted to other individuals. The
polymerase (POL) gene overlaps the surface (S) gene. Thus, during treatment, mutations in the POL gene may lead
to changes in hepatitis B surface antigen (HBsAg). The purpose of this study was to evaluate the frequency of
lamivudine and vaccine escape mutations in HBsAg-positive blood donors from the city of Santos and in untreated
HBV mono-infected patients from the city of São Paulo, Brazil.
Methods: HBV DNA was extracted from 80 serum samples, of which 61 were from volunteer blood donors and 19
were from untreated HBV patients. A fragment of the POL/S genes containing 593 base pairs was amplified using
nested PCR. Thirty four were PCR-positive and sequencing was performed using an ABI Prism 3130 Genetic
Analyzer. Alignments and mutation mapping were performed using BioEdit software.
Results: HBV DNA from 21 blood donors and 13 untreated patient samples were characterized using nucleotide
sequencing PCR products from the POL/S genes. We were able to detect one sample with the resistance mutation to
lamivudine rtM204V + rtL180M (2.94%), which was found in a volunteer blood donor that has never used antiviral drugs.
The other samples showed only compensatory mutations, such as rtL80F (5.88%), rtL80V (2.94%), rtL82V + rtV207L
(2.94%), rtT128P (5.88%), rtT128N/S (2.94%) and rtS219A (5.88%). We found modifications in the S gene in 14 of the 34
samples (41.16%). The mutations detected were as follows: sM133L + sI195T (2.94%), sI195M (2.94%), sP120T (2.94%),
sY100S/F (2.94%), sY100C (17.64%), sI/T126P + sQ129P (2.94%), sM198I + sF183C (2.94%) and sS210R (5.88%).
Conclusions: Our results suggest the transmission of lamivudine-resistant forms. Thus, the evaluation of HBV-infected
subjects for lamivudine resistance would improve treatment regime. Moreover, the mutations in the S gene may impair
HBsAg antigenicity and contribute to HBsAg failure detection and vaccine escape.
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Figure 1 Phylogenetic relationship generated from 34 HBV
sequences. A bootstrap analysis with 1,000 replications was
performed to confirm the reliability of the tree. The approximate
likelihood ratio test (aLRT) values≥ 70% are indicated at the nodes.
Nucleotide sequences were compared with reference sequences,
which are indicated by accession number and alphabetical letter.
Samples from the Blood Center of Santos are indicated with squares,
and those from São Paulo are indicated with triangles.
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Transmitted drug resistance (TDR) may impair or dimin-
ish a disease response to treatment by transmitting direct
or cross-resistance among drugs. Resistance to lamivudine
(LAM) increases the potential for cross-resistance to other
nucleos(t)ide analogs (emtricitabine, telbivudine and cle-
vudine and partial cross-resistance to entecavir), limiting
treatment options [1]. There are few studies regarding the
incidence of transmitted resistance to LAM. Moreover,
the results differ among countries worldwide [2-5].
Resistance mutations caused by LAM can lead to changes
in the amino acids in the surface antigen (HBsAg) because
of the overlap between the polymerase (POL) and the sur-
face (S) gene. These changes may compromise the patient’s
response to the infection and to the vaccination [6,7].
Santos is the location of the most important seaport in
Latin America. As such, it receives a large number of
visitors from different countries and presents high levels
of TDR to HIV, but there are no data about transmitted
resistance to HBV [8-10]. The risk of contracting hepa-
titis B from blood transfusions in Brazil is 1 in 30,000
donations, and to our knowledge, no data on the distribu-
tion of HBV genotypes or changes in HBsAg are available
for Santos. When combined with risk behaviors (drug use,
men having sex with men and sex work), these factors
may lead to an increased probability of the migration of
LAM-resistant viruses and vaccine escape variants.
The city of São Paulo is considered the main financial
center of Brazil and has a population from different eth-
nicities, which may influence the levels of resistance mu-
tations and the distribution of HBV genotypes.
The aim of this study was to evaluate the frequency
of lamivudine and vaccine escape mutations in HBsAg-
positive blood donors from the city of Santos and in
untreated HBV mono-infected patients from the city of
São Paulo, Brazil.
Results
Genotypes
Of the 34 samples analyzed, 64.7% had Genotype A,
32.35% had Genotype D, and 2.95% had Genotype F.
These results are presented in the phylogenetic tree shown
in Figure 1.
Transmitted drug resistance mutations
Among the 13 subjects from São Paulo, we detected only
the rtS219A + sS210R mutations. All the other modifica-
tions reported in the study were found in the 21 blood
donor subjects from Santos. Modifications within the POL
gene were observed in 9 out of 34 samples (26.47%);
we found only one case with the rtM204V mutation,
which caused complete resistance to LAM, along with
the compensatory mutation rtL180M (2.94%). The other
samples showed only the compensatory mutations rtL80F(5.88%), rtL80V (2.94%), rtL82V + rtV207L (2.94%), rtT128P
(5.88%), rtT128N/S (2.94%) and rtS219A (5.88%).
S Gene modifications
We found modifications in the S gene in 14 of the 34
samples (41.16%). The mutations detected were as follows:
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sY100S/F (2.94%), sY100C (17.64%), sI/T126P + sQ129P
(2.94%), sM198I + sF183C (2.94%) and sS210R (5.88%).
Analyzing both genes together
When the genes were analyzed together, 9 of the 34
samples had mutations in both genes, and we found the
following combinations: sM133L + sI195T with rtL80F +
rtT128P, sI195M with rtL180M + rtM204V, sP120T
with rtT128N, sY100F with rtT128S + rtL80V, sY100S
with rtL80F, sY100C + sI/T126P + sQ129P with rtT128P,
sM198I + sF183C with rtL82V + rtV207L and sS210R with
rtS219A (in two samples), as shown in Table 1.
Discussion
The frequencies of the genotypes found in our study are
in agreement with other studies showing Genotype A as
the most frequent, followed by D and F, in southeastern
Brazil [8]. The Genotype F is endemic in Northern Brazil
[14], nevertheless we indentified this genotype in one
sample from Santos.
The genotype distribution found in the study reflects
the historical context of the Brazilian population, which is
composed of Amerindians and immigrants from Africa
and Europe, although the migration of people from north
and northeast Brazil to southeast also occurs [8]. Although
we were not able to correlate the genotypes with the mu-
tations detected, probably because of the small number
samples analyzed, we found the mutation sF183C in anTable 1 Mutations within the pol and S genes related to antiv
ID Subject Genotype Mutations in combination in
both POL/S genes
Other mu
35 BD D - rtL80F,
39 BD A rtM204V + rtL180M/sI195M
40 BD A rtT128N*/sP120T
55 BD A -
58 BD A -
62 BD D rtS219A*/sS210R*
64 BD A - sI/T126P
65 BD A -
69 BD A rtL8
74 BD A -
75 BD F rtV207L/sM198I
77 BD A -
521 UP A -
1150 UP D rtS219A*/sS210R*
Mutation in bold: Primary mutation related to Lamivudine resistance; Mutations in it
*No in vitro assays; ** Natural polymorphism in the genotype F; ID: Sample identifica
Antigen; POL: Polymerase gene; S: Surface gene; HBIg- Immunoglobulin against Hepindividual infected with genotype F, which corroborates
with other studies that found that this mutation is a nat-
ural polymorphism for genotype F and H [9].
The primary mutation rtM204V reduces susceptibility
to LAM and decreases viral fitness, which is restored by
compensatory mutations [1]. We found the transmitted
mutation rtM204V (2.94%) with the compensatory mu-
tation rtL180M in a blood donor sample. This individual
has never received antiviral treatment; however, we are
not able to inform if this blood donor was vaccinated
against HBV, since this issue is not addressed in the spe-
cific questionnaire used during the donor screening.
Variants harboring both primary and secondary muta-
tions may not substantially reduce their fitness because
the secondary mutations are capable to rescue the fitness
loss caused by the primary mutations [10,14,15]. Then, it is
conceivable that we were able to detect the rtM204V vari-
ant because it was associated with the compensatory muta-
tion at position rt180 (rtL180M), which may recover its
fitness and stability in vivo. In fact, a chimpanzee study
performed by Kamili et al., reported a successful infection
by HBV mutants harboring the mutations rtM204V +
rtL180M, which corroborates our finding that these vari-
ants can be infectious and stable [16].
To our knowledge, no previous studies have evalu-
ated TDR in untreated HBV mono-infected individ-
uals in Brazil. However, among chronically infected and
treated Brazilian individuals, the rate of LAM resistance
(rtM204V + rtL180M) ranges from 16% to 41% [17,18].iral resistance, immune escape and diagnostic failure
tations in POL and S gene Impact of the S gene mutations
sI195T, sM133L*, rtT128P* sI195T- Diagnostic failure and vaccine/HBIg
therapy escape [11]
- sI195M - Impair anti-HBs binding [7]
- sP120T – Vaccine/HBIg therapy escape [12]
rtL80F, sY100S* -
sY100C* -
- -
, sQ129P, rtT128P*, sY100C* sI/T126P and sQ129P- Diagnostic failure [13]
sY100C* -
0V, rtT128S*, sY100F* -
sY100C* -
sF183C**, rtL82V* sM198I - Reduced antigenicity of HBsAg [7]
sF183C**- Reduced anti-HBs binding [9]
sY100C* -
sY100C* -
- -
alic: Compensatory mutations; Underlined Mutations: Have clinical significance;
tion; BD: Blood Donor; UP: Untreated Patient; HBsAg- Hepatitis B Surface
atitis B Virus.
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the mutation rate ranges from 21.42% to 45.45% [19-21].
Mutations in the S gene may lead to diagnostic failure
and vaccine escape because the specific antibodies pro-
duced against HBsAg may not recognize the antigens
produced by the mutated S gene. These mutations were
detected in almost half of the individuals enrolled in our
study, although the role of some of these mutations in
clinical practice is not well understood, as shown in
Table 1. Lai et al. (2012) also found a high level of indi-
viduals infected with HBsAg mutants, from which five
out of eight individuals vaccinated against HBV and
positive for HBV DNA were infected with variants har-
boring S gene mutations. In addition, they found an in-
crease in the detection of HBV serological markers in
adults compared with children and adolescents, suggest-
ing that HBV infection in adults may need new strat-
egies for prevention [22]. sY100C has been reported in
cases of occult hepatitis, however Mello et al. (2011)
found that this mutation did not have any impact for
HBsAg expression and affinity by commercial serologic
assays, which is in agreement with our results that found
this mutation in five HBsAg-positive blood donors [23].
When the POL and S genes were analyzed together, we
found mutations in both genes that can be explained by
their overlapping reading frames in the HBV genome.
Thus, changes at one position may affect the structure
of more than one viral protein. Although we used con-
ventional sequencing technology, among blood donors
and untreated patients, we observed one mutation that
led to loss of susceptibility to LAM as well as some
compensatory mutations capable of restoring viral fit-
ness. Nevertheless, it is worth noting that viral particles
harboring S mutations have a decrease in viral protein
expression and are less infectious when compared with
wild type strains, as observed in in vitro assays [24]. Be-
cause resistance mutations can rapidly decrease follow-
ing the withdrawal of therapy and the absence of drug
selection pressure, it would be interesting to use more
accurate methods, such as next-generation sequencing,
to detect resistance mutations [25].
Conclusions
We observed transmitted resistance mutations in a small
population of HBsAg-positive blood donors and untreated
HBV mono-infected patients. Although we found circula-
tion of POL and S gene mutations, the persistence of these
variants in the absence of therapy is not completely eluci-
dated. Further studies are necessary to clarify the impact of
these mutations for real use in clinics and prevention.
Methods
Eighty samples were collected, of which 61 were from
blood donors and 19 were from HBV untreated patients,between 2008 and 2009 at Santos Blood Center and be-
tween 2007 and 2011 in São Paulo city, respectively. All
of the patients were mono-infected with HBV (HBsAg
positive) and had not received prior treatment with
nucleos(t)ide analogs. The study was approved by the
Ethics Committees and the Institutional Review Board
of the Federal University of Sao Paulo (#0485/09) and
Lusiada Foundation of Santos (#059/2010). Because all
blood donor data were confidential, we did not have ac-
cess to demographic or risk behavior data for these sub-
jects. Regarding the HBV mono-infected patients, 54%
(7) were female, 46% (6) were male, and the average age
was 41 years.
HBV DNA was extracted from serum using a QIAamp
Blood Mini Kit (Qiagen, Valencia, CA, USA). A 593-bp
DNA fragment encompassing the HBV POL and S genes
was amplified using nested PCR [26]. Positive and negative
controls were included at all stages of PCR. Sequencing
was performed using an ABI Prism 3130 Genetic Analyzer
(Applied Biosystems Inc., Foster City, CA). Alignments
were performed using BioEdit Sequence Alignment v. 7.1.5
software [27] and the reference sequence NC003977.1.
Phylogenetic relationships among the individual sequence
types were determined using the neighbor-joining algo-
rithm of MEGA v.4 [28]. The frequencies of resist-
ance mutations were calculated using Fisher’s exact test
(Minitab v. 16) [29].
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